



## **Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics**

November 15, 2016

LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will be presenting two posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2016), taking place November 29 – December 2, 2016 in Munich. The presentations will feature preclinical data from Kura Oncology's KO-947 ERK inhibitor and menin-MLL inhibitor programs. Abstracts are currently available online at the European Cancer Organisation website ([www.ecco-org.eu/Events/ENA2016](http://www.ecco-org.eu/Events/ENA2016)).

### Posters

Date & Time: Nov. 30, 2016, 10:15 a.m. - 5:00 p.m. (CET)

Poster Title: Discovery of novel menin-MLL small molecule inhibitors that display high potency and selectivity in vitro and in vivo

Session: Epigenetic modulators

Abstract Number: 264

Poster Location: P090, ICM – Internationales Congress Center München

Date & Time: Dec. 1, 2016, 10:15 a.m. - 5:00 p.m. (CET)

Poster Title: KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics

Session: Molecular targeted agents II

Abstract Number: 381

Poster Location: P060, ICM – Internationales Congress Center München

### **About Kura Oncology**

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company's website at [www.kuraoncology.com](http://www.kuraoncology.com).

### CONTACT INFORMATION

#### INVESTOR CONTACT:

Robert H. Uhl

Managing Director

Westwicke Partners, LLC

(858) 356-5932

[robert.uhl@westwicke.com](mailto:robert.uhl@westwicke.com)

#### MEDIA CONTACT:

Mark Corbae

Vice President

Canale Communications

(619) 849-5375

[mark@canalecomm.com](mailto:mark@canalecomm.com)



Kura Oncology, Inc.